Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444435 | 1.00 | PDE4B (0.51) | PDE4BP2RX7TACR1GPR119RORC | |
| SCHEMBL5444431 | 1.00 | PDE4B (0.51) | PDE4BP2RX7TACR1GPR119RORC | |
| SCHEMBL19893581 | 0.93 | PDE4B (0.52) | PDE4BTACR1GPR119RORCHSD11B1 | |
| SCHEMBL19893583 | 0.93 | PDE4B (0.52) | PDE4BTACR1GPR119RORCHSD11B1 | |
| SCHEMBL19893582 | 0.93 | PDE4B (0.52) | PDE4BTACR1GPR119RORCHSD11B1 | |
| SCHEMBL5227765 | 0.87 | GPR119 (0.47) | PDE4BP2RX7TACR1GPR119RORC | |
| SCHEMBL5221681 | 0.87 | GPR119 (0.47) | PDE4BP2RX7TACR1GPR119RORC | |
| SCHEMBL5226606 | 0.87 | GPR119 (0.47) | PDE4BP2RX7TACR1GPR119RORC | |
| SCHEMBL4483683 | 0.86 | P2RX7 (0.47) | P2RX7GPR119RORCHSD11B1TP53 | |
| SCHEMBL4483688 | 0.86 | P2RX7 (0.47) | P2RX7GPR119RORCHSD11B1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1789389-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006030984-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | AVPR1B, PRLHR, HRH4 | PDE4B 1273/4885P2RX7 264/4885TACR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.